Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD34+ Cell Therapy in HFpEF
NCT02923609Phase 2Completed
- Sponsor
- University Medical Centre Ljubljana
- Start
- Jan 2016
- Primary completion
- Jan 2022
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CD34+ hematopoietic progenitor cells in heart failure with preserved ejection fraction (HFpEF), sponsored by University Medical Centre Ljubljana. Primary endpoint: Change in left ventricular filling pressures (E/e') at 1 year. Started Jan 2016; status: completed.
02
Drugs
CD34+ hematopoietic progenitor cells
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT02923609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02923609.